- Home
- APLM vs JZXN Comparison
APLM vs JZXN Comparison
Compare APLM & JZXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- JZXN
- Stock Information
- Founded
- APLM 2016
- JZXN 2019
- Country
- APLM United States
- JZXN China
- Employees
- APLM N/A
- JZXN N/A
- Industry
- APLM Blank Checks
- JZXN Retail-Auto Dealers and Gas Stations
- Sector
- APLM Finance
- JZXN Consumer Discretionary
- Exchange
- APLM Nasdaq
- JZXN Nasdaq
- Market Cap
- APLM 6.9M
- JZXN 10.3M
- IPO Year
- APLM N/A
- JZXN 2021
- Fundamental
- Price
- APLM $5.33
- JZXN $1.16
- Analyst Decision
- APLM
- JZXN
- Analyst Count
- APLM 0
- JZXN 0
- Target Price
- APLM N/A
- JZXN N/A
- AVG Volume (30 Days)
- APLM 26.7K
- JZXN 493.3K
- Earning Date
- APLM 08-13-2025
- JZXN 09-08-2025
- Dividend Yield
- APLM N/A
- JZXN N/A
- EPS Growth
- APLM N/A
- JZXN N/A
- EPS
- APLM N/A
- JZXN N/A
- Revenue
- APLM $198,000.00
- JZXN $1,400,139.00
- Revenue This Year
- APLM $415.15
- JZXN N/A
- Revenue Next Year
- APLM N/A
- JZXN N/A
- P/E Ratio
- APLM N/A
- JZXN N/A
- Revenue Growth
- APLM N/A
- JZXN N/A
- 52 Week Low
- APLM $4.47
- JZXN $0.84
- 52 Week High
- APLM $35.98
- JZXN $7.82
- Technical
- Relative Strength Index (RSI)
- APLM 44.49
- JZXN 35.46
- Support Level
- APLM $5.33
- JZXN $0.94
- Resistance Level
- APLM $6.56
- JZXN $1.06
- Average True Range (ATR)
- APLM 0.54
- JZXN 0.09
- MACD
- APLM -0.05
- JZXN 0.09
- Stochastic Oscillator
- APLM 33.11
- JZXN 88.70
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.